We recently compiled a list of the Early Retirement Portfolio: 10 Stocks to Live Off Dividends. In this article, we are going ...

Truist raised the firm’s price target on Bristol Myers (BMY) to $65 from $62 and keeps a Buy rating on the shares as part of a broader research ...

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we ...

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research ...

Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

Bristol Myers Squibb Co. closed $4.40 below its 52-week high ($61.08), which the company achieved on November 11th.

Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $56.57 which represents a decrease of $-0.22 or -0.39% from the prior close of $56.79. The stock opened at $56.34 and touched a low ...

Medtronic (NYSE: MDT), Bristol Myers Squibb (NYSE: BMY), and AbbVie (NYSE: ABBV) have many years of reliable dividend growth under their belts.

Short BMY slightly under 59.95, target 53.71, stop loss @ 60.12 Check the time stamp on this data. Updated AI-Generated ...

The increases are to list prices, which do not include rebates to pharmacy benefit managers and other discounts.

The final trades of the day with CNBC’s Melissa Lee and the Fast Money traders. The first migrant caravan of the year has set ...

Below is Validea's guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY). Of the 22 guru strategies we follow, BMY rates highest using our Multi-Factor Investor model based on the published ...